{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T20:56:05Z","timestamp":1769201765990,"version":"3.49.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1016\/j.pbb.2008.02.006","type":"journal-article","created":{"date-parts":[[2008,2,12]],"date-time":"2008-02-12T15:10:23Z","timestamp":1202829023000},"page":"515-522","source":"Crossref","is-referenced-by-count":28,"title":["Overriding the blockade of antinociceptive actions of opioids in rats treated with extended-release naltrexone"],"prefix":"10.1016","volume":"89","author":[{"given":"Reginald L.","family":"Dean","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark S.","family":"Todtenkopf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel R.","family":"Deaver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahin F.","family":"Arastu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krystal","family":"Reitano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"O'Driscoll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Kriksciukaite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Gastfriend","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbb.2008.02.006_bib1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1476-5381.1972.tb06866.x","article-title":"Time-dose relationships for locomotor activity effects of morphine after acute or repeated treatment","volume":"46","author":"Babbini","year":"1972","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pbb.2008.02.006_bib2","first-page":"341","article-title":"Introduction to early in vitro identification of metabolites of new chemical entities in drug discovery and development","volume":"58","author":"Baranczewski","year":"2006","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pbb.2008.02.006_bib3","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/j.1530-0277.2007.00343.x","article-title":"What role does measuring medication compliance play in evaluating the efficacy of naltrexone?","volume":"31","author":"Baros","year":"2007","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.pbb.2008.02.006_bib4","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1038\/sj.npp.1300274","article-title":"Vivitrex, an injectable, extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for 1\u00a0month in rats","volume":"28","author":"Bartus","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2008.02.006_bib5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0304-3959(95)00088-7","article-title":"Experimental pain stimulates respiration and attenuates morphine-induced respiratory depression: a controlled study in human volunteers","volume":"64","author":"Borgbjerg","year":"1996","journal-title":"Pain"},{"key":"10.1016\/j.pbb.2008.02.006_bib6","first-page":"227","article-title":"Central nervous respiratory depressants\u2013narcotic analgesics","volume":"3","author":"Borison","year":"1977","journal-title":"Pharmacol Ther [B]"},{"key":"10.1016\/j.pbb.2008.02.006_bib7","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/13556210220139541","article-title":"Serum naltrexone and 6-beta-naltrexol levels from naltrexone implants can block very large amounts of heroin: a report of two cases","volume":"7","author":"Brewer","year":"2002","journal-title":"Addict Biol"},{"key":"10.1016\/j.pbb.2008.02.006_bib8","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0022-3565(24)36831-4","article-title":"Sex-related differences in morphine's antinociceptive activity: relationship to serum and brain morphine concentrations","volume":"282","author":"Cicero","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pbb.2008.02.006_bib9","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/archpsyc.63.2.210","article-title":"Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial","volume":"63","author":"Comer","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pbb.2008.02.006_bib10","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2741\/1559","article-title":"The preclinical development of Medisorb Naltrexone, a once a month long acting injection, for the treatment of alcohol dependence","volume":"10","author":"Dean","year":"2005","journal-title":"Front Biosci"},{"key":"10.1016\/j.pbb.2008.02.006_bib11","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1530-0277.2006.00052.x","article-title":"Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone","volume":"30","author":"Dunbar","year":"2006","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.pbb.2008.02.006_bib12","first-page":"483","article-title":"The effects of narcotics and antagonists upon respiration and circulation in man. A review","volume":"1","author":"Eckenhoff","year":"1960","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pbb.2008.02.006_bib13","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jama.293.13.1617","article-title":"Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial","volume":"293","author":"Garbutt","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.pbb.2008.02.006_bib14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1476-5381.1959.tb00924.x","article-title":"Comparative effects of analgesics on pain threshold, respiratory frequency and gastrointestinal propulsion","volume":"14","author":"Green","year":"1959","journal-title":"Br J Pharmacol Chemother"},{"key":"10.1016\/j.pbb.2008.02.006_bib15","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1176\/appi.ps.55.3.221","article-title":"Datapoints: trends in naltrexone use among members of a large private health plan","volume":"55","author":"Harris","year":"2004","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.pbb.2008.02.006_bib16","first-page":"530","article-title":"Naltrexone microspheres: in vitro release and effect on morphine analgesia in mice","volume":"22","author":"He","year":"2001","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.pbb.2008.02.006_bib17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/13556210410001674103","article-title":"Blood naltrexone and 6-beta-naltrexol levels following naltrexone implant: comparing two naltrexone implants","volume":"9","author":"Hulse","year":"2004","journal-title":"Addict Biol"},{"key":"10.1016\/j.pbb.2008.02.006_bib18","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.drugalcdep.2005.02.009","article-title":"Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants","volume":"79","author":"Hulse","year":"2005","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.pbb.2008.02.006_bib19","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00002508-200207001-00002","article-title":"Clinical pharmacology of opioids for pain","volume":"18","author":"Inturrisi","year":"2002","journal-title":"Clin J Pain"},{"key":"10.1016\/j.pbb.2008.02.006_bib20","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1097\/01.ALC.0000139823.30096.52","article-title":"A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence","volume":"28","author":"Johnson","year":"2004","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.pbb.2008.02.006_bib21","doi-asserted-by":"crossref","first-page":"R1287","DOI":"10.1152\/ajpregu.00199.2003","article-title":"Mu-opioid receptor agonist effects on medullary respiratory neurons in the cat: evidence for involvement in certain types of ventilatory disturbances","volume":"285","author":"Lalley","year":"2003","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.pbb.2008.02.006_bib22","first-page":"1207","article-title":"Duration of occupancy of opiate receptors by naltrexone","volume":"29","author":"Lee","year":"1988","journal-title":"J Nucl Med"},{"key":"10.1016\/j.pbb.2008.02.006_bib23","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/0091-3057(94)90258-5","article-title":"A comparison of the antinociceptive effects of opioid agonists in neonatal and adult rats in phasic and tonic nociceptive tests","volume":"49","author":"McLaughlin","year":"1994","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pbb.2008.02.006_bib24","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.pbb.2004.12.002","article-title":"A preclinical comparison between different opioids: antinociceptive versus adverse effects","volume":"80","author":"Meert","year":"2005","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pbb.2008.02.006_bib25","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0376-8716(94)90161-9","article-title":"Determination of naltrexone dosage for narcotic agonist blockade in detoxified Asian addicts","volume":"34","author":"Navaratnam","year":"1994","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.pbb.2008.02.006_bib26","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00063110-200610000-00017","article-title":"Analgesia and sedation in the presence of a naltrexone implant: a novel pharmacological challenge","volume":"13","author":"O'Brien","year":"2006","journal-title":"Eur J Emerg Med"},{"key":"10.1016\/j.pbb.2008.02.006_bib27","first-page":"77A","article-title":"Effects of lead-in abstinence and a goal in abstinence on heavy drinking","volume":"29","author":"O'Malley","year":"2005","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.pbb.2008.02.006_bib28","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s11920-006-0040-0","article-title":"Choosing the right medication for the treatment of alcoholism","volume":"8","author":"Pettinati","year":"2006","journal-title":"Curr Psychiatry Rep"},{"key":"10.1016\/j.pbb.2008.02.006_bib29","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1300\/J069v19n01_06","article-title":"Improving naltrexone response: an intervention for medical practitioners to enhance medication compliance in alcohol dependent patients","volume":"19","author":"Pettinati","year":"2000","journal-title":"J Addict Dis"},{"key":"10.1016\/j.pbb.2008.02.006_bib30","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1124\/jpet.105.087254","article-title":"Morphine side effects in beta-arrestin 2 knockout mice","volume":"314","author":"Raehal","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pbb.2008.02.006_bib31","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2165\/00002018-199207030-00005","article-title":"Adverse effects of systemic opioid analgesics","volume":"7","author":"Schug","year":"1992","journal-title":"Drug Safety"},{"key":"10.1016\/j.pbb.2008.02.006_bib32","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s002130051045","article-title":"Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans","volume":"145","author":"Schuh","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pbb.2008.02.006_bib33","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1164\/ajrccm\/142.4.895","article-title":"Differential roles of opioid receptors in respiration, respiratory disease, and opiate-induced respiratory depression","volume":"142","author":"Shook","year":"1990","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.pbb.2008.02.006_bib34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1472-8206.2006.00459.x","article-title":"Preclinical and clinical pharmacology of alcohol dependence","volume":"21","author":"Tambour","year":"2007","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.pbb.2008.02.006_bib35","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/cpt1976203315","article-title":"Naltrexone: disposition, metabolism, and effects after acute and chronic dosing","volume":"20","author":"Verebey","year":"1976","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pbb.2008.02.006_bib36","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/bmj.332.7534.132","article-title":"Naltrexone and problems in pain management","volume":"332","author":"Vickers","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.pbb.2008.02.006_bib37","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1139\/y98-081","article-title":"Respiratory effects of pressor and depressor agents in conscious rats","volume":"76","author":"Walker","year":"1998","journal-title":"Can J Physiol Pharm"},{"key":"10.1016\/j.pbb.2008.02.006_bib38","series-title":"Textbook of Pain","first-page":"253","article-title":"Central pharmacology of nociceptive transmission","author":"Yaksh","year":"1999"},{"key":"10.1016\/j.pbb.2008.02.006_bib39","first-page":"126","article-title":"Pharmacokinetics and pharmacodynamics of subcutaneous naltrexone pellets in the rat","volume":"237","author":"Yoburn","year":"1986","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305708000531?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305708000531?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T10:32:24Z","timestamp":1737973944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305708000531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["S0091305708000531"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2008.02.006","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}